Production (Stage)
ACADIA Pharmaceuticals Inc.
ACAD
$21.98
$0.432.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 244.32M | 259.60M | 250.40M | 241.96M | 205.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 244.32M | 259.60M | 250.40M | 241.96M | 205.83M |
| Cost of Revenue | 98.66M | 122.53M | 85.46M | 94.46M | 82.63M |
| Gross Profit | 145.66M | 137.07M | 164.94M | 147.50M | 123.20M |
| SG&A Expenses | 126.37M | 130.08M | 118.39M | 117.06M | 107.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 225.03M | 252.61M | 203.86M | 211.53M | 190.62M |
| Operating Income | 19.29M | 6.99M | 46.54M | 30.44M | 15.21M |
| Income Before Tax | 27.78M | 161.09M | 38.81M | 37.18M | 21.00M |
| Income Tax Expenses | 8.79M | 17.34M | 6.04M | 3.79M | 4.45M |
| Earnings from Continuing Operations | 18.99M | 143.74M | 32.77M | 33.39M | 16.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.99M | 143.74M | 32.77M | 33.39M | 16.56M |
| EBIT | 19.29M | 6.99M | 46.54M | 30.44M | 15.21M |
| EBITDA | 22.24M | 12.20M | 49.11M | 33.01M | 20.74M |
| EPS Basic | 0.11 | 0.86 | 0.20 | 0.20 | 0.10 |
| Normalized Basic EPS | 0.10 | 0.05 | 0.20 | 0.14 | 0.08 |
| EPS Diluted | 0.11 | 0.86 | 0.20 | 0.20 | 0.10 |
| Normalized Diluted EPS | 0.10 | 0.05 | 0.20 | 0.14 | 0.08 |
| Average Basic Shares Outstanding | 166.81M | 166.54M | 165.97M | 165.55M | 164.80M |
| Average Diluted Shares Outstanding | 167.67M | 166.70M | 166.18M | 166.17M | 166.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |